公开(公告)号：US20240269124A1

公开(公告)日：2024-08-15

申请号：US18561247

申请日：2022-05-16

Applicant: METANOIA BIO INC.

Inventor： Slavica TUDZAROVA-TRAJKOVSKA ,  Oppel GREEFF ,  Abraham VAN WYK

IPC: A61K31/444 ,  A61K31/165 ,  A61K31/192 ,  A61K31/352 ,  A61K31/382 ,  A61K31/4045 ,  A61K31/4155 ,  A61K31/422 ,  A61K31/495 ,  A61K31/498 ,  A61K31/519 ,  A61K45/06

CPC classification number: A61K31/444 ,  A61K31/165 ,  A61K31/192 ,  A61K31/352 ,  A61K31/382 ,  A61K31/4045 ,  A61K31/4155 ,  A61K31/422 ,  A61K31/495 ,  A61K31/498 ,  A61K31/519 ,  A61K45/06

Abstract: The disclosure relates to methods and compositions for treating neurological conditions such as, such as, neurodegenerative disease, neuropathy, cerebral ischemia; and neurotrauma.

公开(公告)号：US20240262916A1

公开(公告)日：2024-08-08

申请号：US18561127

申请日：2022-05-16

Applicant: METANOIA BIO INC.

Inventor： Slavica TUDZAROVA-TRAJKOVSKA ,  Oppel GREEFF ,  Abraham VAN WYK

IPC: C07K16/28 ,  A61K31/196 ,  A61K31/198 ,  A61K31/245 ,  A61K31/26 ,  A61K31/352 ,  A61K31/357 ,  A61K31/37 ,  A61K31/381 ,  A61K31/403 ,  A61K31/41 ,  A61K31/416 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/498 ,  A61K31/501 ,  A61K31/519 ,  A61K31/661 ,  A61K38/06 ,  A61K38/08 ,  C12N15/113

CPC classification number: C07K16/2857 ,  A61K31/196 ,  A61K31/198 ,  A61K31/245 ,  A61K31/26 ,  A61K31/352 ,  A61K31/357 ,  A61K31/37 ,  A61K31/381 ,  A61K31/403 ,  A61K31/41 ,  A61K31/416 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/498 ,  A61K31/501 ,  A61K31/519 ,  A61K31/661 ,  A61K38/06 ,  A61K38/08 ,  C12N15/1138 ,  C07K2317/569 ,  C12N2310/11

Abstract: The disclosure provides methods and compositions for treating cardiovascular disease with HIF1-a Pathway Inhibitors and PFKFB3 Inhibitors. Exemplary cardiovascular diseases ns treated using the provided methods and compositions include acute coronary syndrome, coronary artery disease, myocardial infarction, coronary heart disease, carditis or cardiomyopathy, an ischemic cardiovascular disease, heart failure, stroke, peripheral vascular disease peripheral arterial disease, and ischemia/reperfusion injury.

公开(公告)号：US20240269111A1

公开(公告)日：2024-08-15

申请号：US18561103

申请日：2022-05-16

Applicant: METANOIA BIO INC.

Inventor： Margaretha ROUX ,  Slavica TUDZAROVA-TRAJKOVSKA ,  Abraham VAN WYK

IPC: A61K31/404 ,  A61K31/196 ,  A61K31/245 ,  A61K31/352 ,  A61K31/381 ,  A61K31/403 ,  A61K31/41 ,  A61K31/4155 ,  A61K31/422 ,  A61K31/427 ,  A61K31/444 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/498 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  A61K45/06

CPC classification number: A61K31/404 ,  A61K31/196 ,  A61K31/245 ,  A61K31/352 ,  A61K31/381 ,  A61K31/403 ,  A61K31/41 ,  A61K31/4155 ,  A61K31/422 ,  A61K31/427 ,  A61K31/444 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/498 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  A61K45/06

Abstract: The disclosure provides compositions and methods for treating ocular neovascular diseases and conditions with HIF1-α Pathway Inhibitors and PFKFB3 Inhibitors. Exemplary ocular neovascular diseases and conditions treated using the provided compositions and methods include diabetic retinopathy, diabetic macular edema, age-related macular degeneration, and choroidal neovascular membranes.